Aspirin for Primary Cardiovascular Prevention in Patients with Family History of Cardiovascular Disease: Meta-analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Baigent C, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.
Caldeira D, et al. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: systematic review and meta-analysis. Prim Care Diabetes. 2019.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–646.
Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. Jama. 2014;312(23):2510–20.
Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JAE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304.
Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321(3):129–35.
Rivera CM, Song J, Copeland L, Buirge C, Ory M, McNeal CJ. Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. J Women’s Health (Larchmt). 2012;21(4):379–87.